Speaking of Urology: ASCO GU 2023 Highlights

In this episode of Speaking of Urology®, Laura Bukavina, MD, MPH, and Kyle Rose, MD, discuss some of the notable abstracts that were presented at the American Society of Clinical Oncology (ASCO) Gastrourinary (GU) Cancers Symposium, which was held January 16-18, 2023 in San Francisco, California. Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Rose is a urologic oncology fellow at Moffitt Cancer Center in Tampa, Florida.

This recap was originally presented by Dr. Bukavina and Dr. Rose during the inaugural live Twitter Spaces event held by Urology Times. In the discussion, Bukavina and Rose touched on the following abstracts:

• “A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN),” presented by Daniel M. Geynisman
• “Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON),” presented by Brian M. Shuch, MD
• “Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non–muscle-invasive bladder cancer: A prospective study,” presented by Kyle Rose, MD
• “Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC),” presented by Toni K. Choueiri
• “Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) by disease volume and disease risk in the phase 3 ARASENS study,” presented by Maha H. A. Hussain

Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.